Genmab shares fall 3% after Q3 revenue slightly misses expectations

Genmab’s third-quarter revenue of $1.19 billion slightly missed the $1.2 billion consensus, while EPS of $0.55 beat the $0.35 estimate; operating expenses rose 35% to $2.02 billion and operating profit fell to $986 million from $1.01 billion. The company maintained full-year guidance, and revenue for the first nine months of 2026 increased 22% to $3.24 billion, with higher royalties and Epkinly sales. Shares fell more than 3% the day after results; Genmab cited recent pivotal data and potential 2027 launches for three late-stage drugs.

Analysis

The key valuation tension is whether Genmab’s spending converts into durable, owned launch economics or merely raises the cost base ahead of uncertain approvals. The EPS beat and higher adjusted operating profit soften the quarter’s headline weakness, but they do not resolve that conversion question; unchanged guidance limits near-term estimate risk while leaving the 2027 launch case dependent on trial data, regulatory timing, and commercial execution. In the next 1–3 months, pivotal-data readouts and submission details can outweigh the modest revenue miss. Over 6–18 months, successful launches could diversify Genmab beyond royalties tied to partner products; delays or weak uptake would leave the larger expense base exposed and reinforce concentration in partner-generated royalties. For JNJ, stronger Darzalex sales support product momentum, but the read-through to JNJ equity is diluted by its broader portfolio and the economics of Genmab’s royalty arrangement, which should be verified before sizing a relative-value trade. The contrarian point: treating the expense increase as purely negative may miss pipeline investment and integration costs, but treating adjusted profit growth as proof of attractive launch returns is equally premature. The thesis is falsified positively by supportive late-stage data, timely filings, and improving launch contribution; negatively by guidance cuts, trial setbacks, or evidence that expenses continue rising without measurable product contribution.

Key Decisions for Investors

• Avoid chasing the immediate GMAB decline or initiating a short solely on the expense headline: catalysts are close, guidance is unchanged, and the data do not yet establish a deteriorating earnings trajectory.
• Keep GMAB on a catalyst watch for the fourth-quarter data. Consider a small, risk-defined bullish position only after reviewing the actual efficacy/safety disclosures and regulatory path; do not pay for event optionality without checking implied volatility and the event calendar.
• Before treating 2027 launches as a valuation catalyst, verify product-specific economics, expected launch costs, partner responsibilities, and whether submissions are accepted on the stated timetable. A delayed filing or weaker-than-expected pivotal data would invalidate the upside setup.
• Treat JNJ as a secondary read-through, not a clean hedge: confirm the royalty and collaboration terms before trading JNJ against GMAB. Reassess if Darzalex sales momentum weakens or Genmab’s guidance is revised.